-

MindMed to Host Investor Day June 2023

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20th, 2023 that will focus on the MM-120 program in generalized anxiety disorder (GAD). In person attendance is by invitation only. All others are invited to participate via the live webcast.

MindMed’s 2023 Analyst Day

Date and Time: June 20th, 2023 at 9:30am ET
Registration: Virtual Registration Link

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Resources website for up to 90 days following the event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Contacts

For Media & Investor Inquiries:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co

Industry:

Mind Medicine

NASDAQ:MNMD
Release Summary
MindMed will a host an Analyst Day on Tuesday, June 20th that will focus on the MM-120 program in generalized anxiety disorder (GAD).
Release Versions
English
$Cashtags
$MNMD

Contacts

For Media & Investor Inquiries:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co

Social Media Profiles
MindMed on LinkedIn
More News From Mind Medicine

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September...

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s third...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares of the Company (the "Options") with effective grant dates of September 14,...
Back to Newsroom